Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

NCT07080905 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia B

Interventions

GENETIC: CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua)

Sponsor

CSL Behring